Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors-Reference-Cited by-同舟云学术

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors

Published:2017-04-25 Issue:16 Volume:123 Page:3080-3087
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Moore Kathleen N.¹^ORCID,Borghaei Hossein²,O'Malley David M.³,Jeong Woondong⁴,Seward Shelly M.⁵,Bauer Todd M.⁶,Perez Raymond P.⁷,Matulonis Ursula A.⁸,Running Kelli L.⁹,Zhang Xiaoyan⁹,Ponte Jose F.⁹,Ruiz-Soto Rodrigo⁹,Birrer Michael J.¹⁰

Affiliation:

1. Department of Obstetrics and Gynecology; University of Oklahoma Health Sciences Center; Oklahoma City Oklahoma

2. Department of Hematology/Oncology; Fox Chase Cancer Center; Philadelphia Pennsylvania

3. Department of Obstetrics and Gynecology; The Ohio State University College of Medicine; Columbus Ohio

4. Cancer Therapy and Research Center; University of Texas Health Science Center; San Antonio Texas

5. Department of Obstetrics and Gynecology; Wayne State University; Detroit Michigan

6. Sarah Cannon Research Institute/Tennessee Oncology; PLLC; Nashville Tennessee

7. Division of Hematology/Oncology, University of Kansas; Fairway Kansas

8. Department of Medical Oncology; Dana Farber Cancer Institute; Boston Massachusetts

9. ImmunoGen, Inc.; Waltham Massachusetts

10. Gillette Center for Gynecologic Oncology; Massachusetts General Hospital; Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference33 articles.

1. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity;Frei;Clin Cancer Res.,1998

2. Targeted cancer therapy: conferring specificity to cytotoxic drugs;Chari;Acc Chem Res.,2008

3. Proteins: emerging carrier for delivery of cancer therapeutics;Yewale;Expert Opin Drug Deliv.,2013

4. Peptides, proteins and peptide/protein-polymer conjugates as drug delivery system;Mukherjee;Protein Pept Lett.,2014

5. Antibody-drug conjugates: an emerging concept in cancer therapy;Chari;Angewandte Chemie.,2014

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of antibody–drug conjugates in gynecologic cancer;Holistic Integrative Oncology;2024-08-29

2. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy;Journal of Ovarian Research;2024-08-08

3. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer;Future Oncology;2024-07-31

4. The clinical landscape of antibody-drug conjugates in endometrial cancer;International Journal of Gynecologic Cancer;2024-07-29

5. Unsolved Issues in the Integrated Histo-Molecular Classification of Endometrial Carcinoma and Therapeutic Implications;Cancers;2024-07-04